The field of cancer genetics is at an exciting juncture in which the tools for interrogating cancer genes, genomes and networks have progressed enormously. The overall goal of the Cancer Genomes and Networks program (CGN) is to create a fertile environment for research on genetic abnormalities causing, or consistently associating with, the induction and progression of neoplasia and its systemic effects, and then to apply insights from these studies to clinical and translational research and patient treatment. The program is organized into four themes: Cancer genomes and genome integrity. Cancer epigenomes and transcriptional networks, Cancer proteomes and protein signaling networks, and Cancer metabolomes and metabolic networks. The CGN program has 31 members from 11 academic departments with $18.5 Million of peer reviewed research grant funding (annual direct costs). Members of the CGN program published 814 programmatically aligned articles since 2007, 10% were the result of intra-programmatic collaborations, 14% were inter-programmatic. The Cancer Center adds value to CGN by providing shared resource facilities, human tissue samples, and pilot project grants for translational research. The CGN program adds value to the Cancer Center by developing new methods/ technologies for high throughput analyses of complex biological systems that in the long run will benefit the diagnosis and the treatment of cancer.

Public Health Relevance

There is growing optimism that knowledge of the genetic make-up of individual tumors will allow both a greater understanding of the development of cancer and more successful individualized treatment of cancer. The CGN program will contribute to this goal through its focus on state-of-the-art genetics and genomics methods and their application to cancer research and treatment

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Diego
La Jolla
United States
Zip Code
Akers, Johnny C; Ramakrishnan, Valya; Yang, Isaac et al. (2016) Optimizing preservation of extracellular vesicular miRNAs derived from clinical cerebrospinal fluid. Cancer Biomark 17:125-32
Hoffmann, Hanne M; Trang, Crystal; Gong, Ping et al. (2016) Deletion of Vax1 from Gonadotropin-Releasing Hormone (GnRH) Neurons Abolishes GnRH Expression and Leads to Hypogonadism and Infertility. J Neurosci 36:3506-18
Baumgartner, Joel M; Kwong, Thomas G; Ma, Grace L et al. (2016) A Novel Tool for Predicting Major Complications After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy. Ann Surg Oncol 23:1609-17
Meyskens Jr, Frank L; Mukhtar, Hasan; Rock, Cheryl L et al. (2016) Cancer Prevention: Obstacles, Challenges and the Road Ahead. J Natl Cancer Inst 108:
Hussain, Timon; Savariar, Elamprakash N; Diaz-Perez, Julio A et al. (2016) Surgical molecular navigation with ratiometric activatable cell penetrating peptide for intraoperative identification and resection of small salivary gland cancers. Head Neck 38:715-23
Singh, Alok R; Joshi, Shweta; Zulcic, Muamera et al. (2016) PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma. PLoS One 11:e0150836
Liu, Lin; Messer, Karen; Baron, John A et al. (2016) A prognostic model for advanced colorectal neoplasia recurrence. Cancer Causes Control 27:1175-85
Nuyen, Brian A; Fox, Rina S; Malcarne, Vanessa L et al. (2016) Excessive Daytime Sleepiness as an Indicator of Depression in Hispanic Americans. Hisp Health Care Int 14:116-23
Ghosh, Pradipta; Aznar, Nicolas; Swanson, Lee et al. (2016) Biochemical, Biophysical and Cellular Techniques to Study the Guanine Nucleotide Exchange Factor, GIV/Girdin. Curr Protoc Chem Biol 8:265-298
Johns, Claire; Seav, Susan M; Dominick, Sally A et al. (2016) Informing hot flash treatment decisions for breast cancer survivors: a systematic review of randomized trials comparing active interventions. Breast Cancer Res Treat 156:415-26

Showing the most recent 10 out of 699 publications